Last reviewed · How we verify

NCT03421509

Cutaneous Silent Period and Spasticity

Status unknown Last updated 3 July 2018
What this trial tests

trial testing cutaneous silent period in Stroke in 50 participants. Status unknown.

Timeline
1 July 2018
Primary endpoint
1 January 2019
1 February 2019

Quick facts

Lead sponsorMarmara University
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment50
Start date1 July 2018
Primary completion1 January 2019
Estimated completion1 February 2019
Sites1 location across Turkey (Türkiye)

Drugs / interventions tested

Conditions studied

Sponsor

Marmara University

Who can join

Adults 18 to 80, any sex, with Stroke. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The cutaneous silent period (CSP) is a brief transient suppression of the voluntary muscle contraction that follows a noxious cutaneous nerve stimulation. Studies in patients with central disorders of motor control such as dystonia and Parkinson's disease have shown CSP abnormalities indicating that supraspinal pathways influence this inhibitory spinal reflex. The aim of this study is to investigate the association between CSP parameters (duration and latency) and spasticity in stroke.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of cutaneous silent period

Trials testing the same drug.

Other recruiting trials for Stroke

Currently open trials in the same condition.

Other Marmara University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03421509.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing